MX2017014768A - Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios. - Google Patents

Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.

Info

Publication number
MX2017014768A
MX2017014768A MX2017014768A MX2017014768A MX2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A
Authority
MX
Mexico
Prior art keywords
methods
compositions
progestin
shbg
effectiveness
Prior art date
Application number
MX2017014768A
Other languages
English (en)
Spanish (es)
Inventor
Macfarlane Katie
E Kafrissen Michael
Kydonieus Agis
Original Assignee
Agile Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agile Therapeutics Inc filed Critical Agile Therapeutics Inc
Publication of MX2017014768A publication Critical patent/MX2017014768A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2017014768A 2015-05-18 2016-05-18 Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios. MX2017014768A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163113P 2015-05-18 2015-05-18
US201562254999P 2015-11-13 2015-11-13
PCT/US2016/033024 WO2016187269A1 (en) 2015-05-18 2016-05-18 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Publications (1)

Publication Number Publication Date
MX2017014768A true MX2017014768A (es) 2018-03-23

Family

ID=56116539

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014768A MX2017014768A (es) 2015-05-18 2016-05-18 Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.

Country Status (10)

Country Link
US (3) US20180125860A1 (https=)
EP (1) EP3297634A1 (https=)
JP (2) JP2018515552A (https=)
CN (1) CN107995864A (https=)
AU (2) AU2016264137B2 (https=)
BR (1) BR112017024783A2 (https=)
CA (1) CA2986039A1 (https=)
HK (1) HK1251938A1 (https=)
MX (1) MX2017014768A (https=)
WO (1) WO2016187269A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200129524A1 (en) * 2017-03-15 2020-04-30 Agile Therapeutics, Inc. Personalized contraceptive formulations
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US4863738A (en) 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) * 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
CN1188189C (zh) 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
BR0015802B1 (pt) * 1999-11-24 2014-04-29 Agile Therapeutics Inc Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
JP4965263B2 (ja) * 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
US20100178323A1 (en) * 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
CA2704117C (en) 2007-11-02 2015-11-17 Acrux Dds Pty Ltd Transdermal delivery system
ES2734510T3 (es) * 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
CA2740004A1 (en) * 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198919B2 (en) * 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2410859A4 (en) * 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
EP2806862A2 (en) 2012-01-27 2014-12-03 Agile Therapeutics, Inc. Transdermal hormone delivery
EA030797B1 (ru) * 2012-12-21 2018-09-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Система трансдермальной доставки гормонов (варианты) и способы ее применения

Also Published As

Publication number Publication date
HK1251938A1 (zh) 2019-05-03
US20240156838A1 (en) 2024-05-16
AU2021262853B2 (en) 2024-05-09
CN107995864A (zh) 2018-05-04
CA2986039A1 (en) 2016-11-24
JP2021169503A (ja) 2021-10-28
US20250319102A1 (en) 2025-10-16
AU2021262853A1 (en) 2021-12-02
EP3297634A1 (en) 2018-03-28
BR112017024783A2 (pt) 2018-08-07
AU2016264137B2 (en) 2021-08-19
JP2018515552A (ja) 2018-06-14
WO2016187269A1 (en) 2016-11-24
AU2016264137A1 (en) 2018-01-18
US20180125860A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
MX2017014768A (es) Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
BR112018003877A2 (pt) “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
CL2016001809A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).
NI201700173A (es) Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
DOP2015000274A (es) Compuestos químicos
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
BR112016029338A2 (pt) creme transdérmico
BR112014031910A2 (pt) formulações e terapias naturais de combinação para reposição hormonal
MX2018011706A (es) Composicion farmaceutica de hormona esteroide.
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
DOP2012000325A (es) Derivados de 6,7-dihidro-5h-benzo (7)anulenos, metodos para su preparacion, preparaciones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
MX2016014281A (es) Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
BR112016023766A2 (pt) fralda descartável
CL2017001840A1 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.
ES2948324A8 (es) Proceso para preparar (15alfa,16alfa,17beta)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol monohidrato (Estetrol monohidrato)
MX2019003685A (es) Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
CO2017001918A2 (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2018001653A1 (es) Concentrados en emulsión de compuestos lipofílicos
MX2017013879A (es) Composiciones que comprenden anakinra.